[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341074-105":59,"doc-detail-341074-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","translational-therapeutics-redefining-cancer-research-for-therapeutic-breakthroughs","Translational Therapeutics - Redefining cancer research for therapeutic breakthroughs","","Cancer research has been heavily funded for decades, yet translating basic findings into major advances in treatment remains limited. This perspective analyzes why innovation in cancer research is slow to become clinical breakthroughs and outlines strategies to accelerate discovery. It discusses how current pillars of therapy still rely on surgery, chemotherapy, and radiotherapy, while targeted therapies and immunotherapies face constraints in eligibility, cost, availability, and resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/translational-therapeutics-redefining-cancer-research-for-therapeutic-breakthroughs/341074/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/translational-therapeutics-redefining-cancer-research-for-therapeutic-breakthroughs/341074.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why has investment in cancer research not fully translated into breakthroughs in treatment?","Question",{"text":112,"@type":113},"Despite large funding, the translation into substantial treatment advances has been limited. The article attributes slow progress to factors affecting innovation and clinical adoption.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the main limitations of targeted therapies and immunotherapies mentioned in the perspective?",{"text":117,"@type":113},"Key pitfalls include restricted applicability to specific molecular subsets, high costs, limited availability, and tumor resistance to therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How does methodological reductionism support evidence-based medicine, and why may it fall short for cancer?",{"text":121,"@type":113},"Randomized clinical trials and related studies break complex interventions into components to assess individual effects. However, reductionism may not fully explain multifactorial disorders like cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341074,1790599043,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nPERSPECTIVE OPEN   \nTranslational Therapeutics  \nRedeﬁning cancer research for therapeutic breakthroughs  \n 1 ✉  \nArseniy E. Yuzhalin   \n© The Author(s) 2024  \n\n|  | Cancer research has played a pivotal role in improving patient outcomes. However, despite the signiﬁcant investment in fundamental cancer research over the past few decades, the translation of funding into substantial advancements in cancer treatment has been limited. This perspective article employs a detailed analysis to outline strategies for promoting innovation and |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n| facilitating discoveries within the ﬁeld of cancer research. |  |  |\n|  | British Journal of Cancer (2024) 130:1078–1082; [https://doi.org/10.1038/s41416-024-02634-6](https://doi.org/10.1038/s41416-024-02634-6) |  |\n|  |  |  |\n\nCancer research is among the most heavily funded areas of science. Thousands of original research articles on cancer are published annually; many of these propose novel mechanisms of tumor growth, migration, metastasis, survival, immune escape etc. Many critics have questioned the validity and necessity of such studies, raising concerns over mass generation of irreproducible, redundant, and unjustiﬁed research, both basic and clinical [1–5] . Remarkably, the three primary pillars of cancer treatment—surgery, chemotherapy, and radiotherapy—which were actively employed at least 60 years ago, continue to serve as the key treatment options today. We have witnessed a dramatic rise in the survival rates of patients undergoing treatment with chemotherapy and radiotherapy. However, these improvements have primarily stemmed from the development of more effective chemotherapy agents [6] and their combinations [7, 8] and the evolution of radiotherapy approaches, owing to signiﬁcant advancements in technology. Earlier diagnosis, improved stratiﬁcation and better management of treatments have further contributed to improved survival. Certainly, novel targeted therapies and immunotherapies have provided great beneﬁts for cancer patients in recent decades. Unfortunately, these treatments are burdened with multiple pitfalls, including: (i) their applicability being restricted to a speciﬁc molecular subset of cancer patients,(ii) exorbitant costs, (iii) limited availability, and (iv) tumors’developing resistance to therapy. Indeed, only ~40% of cancer patients in the United States were eligible to receive immune checkpoint inhibitors in 2018, and only 12.46% of these patients responded to therapy [9] . The cost of these therapies presents another critical issue. For example, the total treatment expense for chimeric antigen receptor T-cell therapy has been estimated to reach up to $500,000 for patients experiencing severe cytokine release syndrome, which is a common adverse reaction to this type of treatment [10] . Furthermore, the availability of targeted therapies and immunotherapies in low- and middle-income countries is minimal [11]; thus, 85% of the world’s population still relies on surgery, chemotherapy, and radiotherapy for cancer  \ntreatment. Additionally, while most targeted therapies and immunotherapies extend a patient’s survival, they are rarely, if ever, 100% curative without surgery and/or intensive chemo-/ radiotherapy regimens. Resistance to targeted therapy is frequently inevitable and leads to tumor recurrence in most patients [12] . For example, BRAF-targeting drugs radically changed the clinical practice in melanoma treatment, extending median survival from 6 to 30 months [13] . However, most patients with BRAF-mutated metastatic melanoma experience a relapse in the ﬁrst year after targeted therapy discontinuation, of which 50% occur in the ﬁrst 3 months [14] . Clearly, innovative approaches for cancer treatment are urgently needed. Thus, it would be valuable to explore the reasons behind the stumbling progress of inno","cbCaiqCu8lQQG0tz","https://ap.wps.com/l/cbCaiqCu8lQQG0tz","pdf",680821,"English","# Background and limitations in cancer research translation\n# Current treatment landscape and key challenges\n# Evidence-based medicine and methodological reductionism\n# Strategies to promote innovation in cancer research","[{\"question\":\"Why has investment in cancer research not fully translated into breakthroughs in treatment?\",\"answer\":\"Despite large funding, the translation into substantial treatment advances has been limited. The article attributes slow progress to factors affecting innovation and clinical adoption.\"},{\"question\":\"What are the main limitations of targeted therapies and immunotherapies mentioned in the perspective?\",\"answer\":\"Key pitfalls include restricted applicability to specific molecular subsets, high costs, limited availability, and tumor resistance to therapy.\"},{\"question\":\"How does methodological reductionism support evidence-based medicine, and why may it fall short for cancer?\",\"answer\":\"Randomized clinical trials and related studies break complex interventions into components to assess individual effects. However, reductionism may not fully explain multifactorial disorders like cancer.\"}]","Translational Therapeutics - Redefining cancer research for therapeutic breakthroughs | PDF",1790040162,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b75177dd182aedc5717955e8ac725ac.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8873d84a1fb39e9c6c77902a348e0265.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94ae7d9bc4e23fd3a3fac9155f374907.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4403010173bb4026359244807f1f4eb.webp",980,1301]